MCID: PST005
MIFTS: 52

Posterior Uveitis

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Posterior Uveitis

MalaCards integrated aliases for Posterior Uveitis:

Name: Posterior Uveitis 12 75 53 59 15 17
Uveitis, Posterior 12 75 44 72
Uveitis Posterior 55
Choroiditis 59

Characteristics:

Orphanet epidemiological data:

59
posterior uveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12574
MeSH 44 D015866
NCIt 50 C35111
SNOMED-CT 68 43363007 46627006
ICD10 via Orphanet 34 H30.0 H30.1 H30.2 more
UMLS via Orphanet 73 C0008526 C0042167
Orphanet 59 ORPHA280892
UMLS 72 C0042167

Summaries for Posterior Uveitis

MalaCards based summary : Posterior Uveitis, also known as uveitis, posterior, is related to chorioretinitis and choroiditis, and has symptoms including eye manifestations An important gene associated with Posterior Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Allograft rejection. The drugs Fluocinolone Acetonide and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are immune system and mortality/aging

Wikipedia : 75 Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the... more...

Related Diseases for Posterior Uveitis

Diseases in the Uveitis family:

Autoimmune Uveitis Posterior Uveitis
Intermediate Uveitis Infectious Anterior Uveitis
Anterior Uveitis Infectious Posterior Uveitis
Systemic Diseases with Anterior Uveitis Systemic Diseases with Posterior Uveitis

Diseases related to Posterior Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1750)
# Related Disease Score Top Affiliating Genes
1 chorioretinitis 32.9 SAG RBP3
2 choroiditis 32.7 TNF CFH
3 macular retinal edema 31.2 IL6 CAPN5
4 miliary tuberculosis 31.1 TNF IFNG
5 scleritis 31.0 TNF IFNG
6 uveal disease 30.9 TNF SAG RBP3 IL6
7 panuveitis 30.9 TNF SAG RBP3
8 toxoplasmosis 30.7 TNF IL6 IFNG
9 multifocal choroiditis 30.7 TNF CFH
10 cytomegalovirus retinitis 30.7 TNF IFNG
11 soft tissue sarcoma 30.5 TNF IFNG
12 meningitis 30.4 TNF IL6 IFNG
13 retinitis pigmentosa 55 30.4 TNF IL6
14 sarcoidosis 1 30.4 TNF IL2RA IL2 IFNG
15 poems syndrome 30.3 TNF IL6
16 poliomyelitis 30.3 TNF IFNG
17 proteasome-associated autoinflammatory syndrome 1 30.3 TNF IL6 IFNG
18 uveitis 30.2 TNF SAG RBP3 IL2RA IFNG CAPN5
19 lymphopenia 30.1 IL2RA IL2 IFNG
20 progressive multifocal leukoencephalopathy 30.1 TNF IL2
21 schistosomiasis 30.1 TNF IL2 IFNG
22 central nervous system disease 30.0 TNF IL6 IFNG
23 temporal arteritis 30.0 TNF IL6 IFNG
24 rheumatic disease 30.0 TNF IL2RA IFNG
25 nervous system disease 30.0 TNF IL6 IFNG
26 chlamydia 30.0 TNF IL6 IFNG
27 exanthem 30.0 TNF IL6 IL2
28 pulmonary tuberculosis 29.9 TNF IL2 IFNG
29 bacterial infectious disease 29.9 TNF IL6 IFNG
30 anterior uveitis 29.9 IL6 IL2RA CFH
31 leptospirosis 29.9 TNF IL6 IFNG
32 measles 29.9 IL6 IL2 IFNG
33 connective tissue disease 29.8 TNF IL6 IFNG
34 aseptic meningitis 29.8 TNF IFNG
35 erythema multiforme 29.8 TNF IL2 IFNG
36 juvenile rheumatoid arthritis 29.8 TNF IL6 IL2RA
37 myeloma, multiple 29.8 TNF IL6 IL2
38 listeriosis 29.8 TNF IL6
39 histoplasmosis 29.7 IFNG CFH
40 chronic graft versus host disease 29.7 TNF IL2RA IFNG
41 conjunctivitis 29.7 IL6 IL2 IFNG
42 extramedullary plasmacytoma 29.7 IL6 IL2
43 contact dermatitis 29.7 TNF IL6 IFNG
44 intermediate uveitis 29.7 TNF IL6 IL2RA IL2 IFNG
45 viral meningitis 29.6 IL6 IFNG
46 crohn's colitis 29.6 TNF IL2 IFNG
47 localized scleroderma 29.6 TNF IL6
48 visceral leishmaniasis 29.5 TNF IL2 IFNG
49 myasthenia gravis 29.5 TNF IL2 IFNG
50 human immunodeficiency virus type 1 29.5 TNF IL6 IL2 IFNG

Graphical network of the top 20 diseases related to Posterior Uveitis:



Diseases related to Posterior Uveitis

Symptoms & Phenotypes for Posterior Uveitis

UMLS symptoms related to Posterior Uveitis:


eye manifestations

MGI Mouse Phenotypes related to Posterior Uveitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.7 CAPN5 CFH IFNG IL2 IL2RA IL6
2 mortality/aging MP:0010768 9.56 CAPN5 CFH IFNG IL2 IL2RA IL6
3 vision/eye MP:0005391 9.28 CFH IFNG IL2 IL2RA IL6 KIAA1109

Drugs & Therapeutics for Posterior Uveitis

Drugs for Posterior Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Chlorambucil Approved Phase 4 305-03-3 2708
8
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Infliximab Approved Phase 4 170277-31-3
11
Azathioprine Approved Phase 4 446-86-6 2265
12
Ranibizumab Approved Phase 4 347396-82-1 459903
13
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
14
Choline Approved, Nutraceutical Phase 4 62-49-7 305
15
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
16 Prednisolone acetate Phase 4
17 Methylprednisolone Acetate Phase 4
18 Neuroprotective Agents Phase 4
19 Protective Agents Phase 4
20 Cyclosporins Phase 4
21 Angiogenesis Inhibitors Phase 4
22 Angiogenesis Modulating Agents Phase 4
23 Alkylating Agents Phase 4
24 Antitubercular Agents Phase 4
25 Antineoplastic Agents, Alkylating Phase 4
26 Cathartics Phase 4
27 Carboxymethylcellulose Sodium Phase 4
28 Laxatives Phase 4
29 Nootropic Agents Phase 4
30 Cytidine Diphosphate Choline Phase 4
31 Adrenocorticotropic Hormone Phase 4
32 Melanocyte-Stimulating Hormones Phase 4
33 beta-endorphin Phase 4
34
Adalimumab Approved Phase 3 331731-18-1 16219006
35 Interferon alpha-2 Phase 3
36 Interferon-alpha Phase 3
37 interferons Phase 3
38 Antiviral Agents Phase 3
39 Calcineurin Inhibitors Phase 3
40 Ophthalmic Solutions Phase 3
41 Antibodies Phase 3
42 Antibodies, Monoclonal Phase 3
43 Immunoglobulins Phase 3
44 Pharmaceutical Solutions Phase 3
45
Denileukin diftitox Approved, Investigational Phase 2 173146-27-5
46
tannic acid Approved Phase 2 1401-55-4
47
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
48
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
49
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Proof of Concept Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy Completed NCT02049476 Phase 4 Dexamethasone pellet
4 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
5 Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
6 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
7 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
8 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
9 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
10 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
11 Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis Active, not recruiting NCT03066869 Phase 4 H.P. ACTHAR GEL
12 Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME) Withdrawn NCT02598869 Phase 4 Triamcinolone Acetonide
13 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
14 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
15 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
16 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
17 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
18 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
19 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
20 A Multicenter, Randomized, Double-Masked, Controlled Study to Evaluate the Safety & Efficacy of Intravitreal Fluocinolone Acetonide (0.59 or 2.1 mg) Implant in Subjects With Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT00407082 Phase 2, Phase 3 fluocinolone acetonide intravitreal implant;Fluocinolone acetonide 2.1mg
21 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
22 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
23 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
24 A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye Completed NCT01358266 Phase 3 DE-109 44 ug;DE-109 440 ug;DE-109 880 ug
25 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
26 Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation Completed NCT00407121 Phase 3 Bevacizumab
27 A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
28 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
29 A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study Terminated NCT02375685 Phase 3
30 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
31 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
32 An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US) Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
33 A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
34 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
35 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01103024 Phase 3
36 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
37 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
38 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
39 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
40 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
41 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
42 Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis Completed NCT00326508 Phase 2 Daclizumab
43 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
44 An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
45 Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome Completed NCT00035906 Phase 2 DEX PS DDS®
46 Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a Completed NCT00508040 Phase 2 interferon alpha 2a;prednisone
47 Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy With Intravitreal Injection of Lucentis (Ranibizumab Injection) Completed NCT00470977 Phase 1, Phase 2 ranibizumab injection (0.5 mg)
48 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
49 Daclizumab for Active, Non-infectious, Sight-threatening Uveitis: A Phase II Pilot Study Completed NCT00070759 Phase 2 Daclizumab
50 A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis Recruiting NCT02911116 Phase 2 Ustekinumab

Search NIH Clinical Center for Posterior Uveitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Corticotropin
Cortisone acetate
Dexamethasone
Hydrocortisone
Methylprednisolone
Prednisolone
Prednisone

Cochrane evidence based reviews: uveitis, posterior

Genetic Tests for Posterior Uveitis

Anatomical Context for Posterior Uveitis

MalaCards organs/tissues related to Posterior Uveitis:

41
Eye, Retina, Endothelial, T Cells, Testes, B Cells, Brain

Publications for Posterior Uveitis

Articles related to Posterior Uveitis:

(show top 50) (show all 1290)
# Title Authors PMID Year
1
Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. 9 38
15878055 2005
2
Serum cytokine receptor levels in noninfectious uveitis. 9 38
15746567 2005
3
Human S-antigen: peptide determinant recognition in uveitis patients. 9 38
15010290 2004
4
Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. 9 38
11263956 2001
5
Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis. 9 38
7882564 1995
6
[Cellular immunoreaction to S-antigen in patients with uveitis and optic neuritis]. 9 38
8223035 1993
7
Distribution of IL-2R and CD45Ro expression on CD4+ and CD8+ T-lymphocytes in the peripheral blood of patients with posterior uveitis. 9 38
1358556 1992
8
Identification of an S-antigen-like molecule in human choroid plexus and cerebrospinal fluid. 9 38
1289136 1992
9
Vision loss with pembrolizumab treatment: A report of two cases. 38
30997872 2019
10
Intravitreal sustained-release dexamethasone implant for the treatment of persistent cystoid macular edema in ocular syphilis. 38
31436209 2019
11
Spectral optical coherence tomography findings in an adult patient with syphilitic bilateral posterior uveitis and unilateral punctate inner retinitis. 38
31211286 2019
12
DETECTION OF TYPE 1 CHOROIDAL NEOVASCULAR MEMBRANES USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN TUBERCULAR POSTERIOR UVEITIS. 38
29689028 2019
13
THE COLLABORATIVE OCULAR TUBERCULOSIS STUDY (COTS)-1: A Multinational Review of 251 Patients With Tubercular Retinal Vasculitis. 38
29697588 2019
14
Local therapy for cancer therapy-associated uveitis: a case series and review of the literature. 38
31409649 2019
15
Clinical features of Chinese patients with relapsing polychondritis. 38
30315131 2019
16
Indicators of Post-Operative Intraocular Pressure Elevation after Naïve Fluocinolone Acetonide Surgical Implantation. 38
31408390 2019
17
Patterns of uveitis in patients with proven systemic (pulmonary and extrapulmonary) tuberculosis. 38
30022332 2019
18
Patterns of Uveitis among Patients Attending Jimma University Department of Ophthalmology, Jimma, Ethiopia. 38
31429610 2019
19
[Clinical features and therapy of uveitis in childhood]. 38
31423830 2019
20
Intra-lenticular caterpillar seta in ophthalmia nodosa. 38
31282202 2019
21
When biology supports clinical diagnosis: review of techniques to diagnose ocular toxoplasmosis. 38
31088793 2019
22
Visual and treatment outcomes of tubercular uveitis: a prospective case series from a referral hospital in Pakistan. 38
31307549 2019
23
Intravitreal dexamethasone implant as an alternative to systemic steroids as prophylaxis for uveitic cataract surgery: a randomized trial. 38
31320735 2019
24
Aetiology of posterior uveitis in a tertiary centre in Finland. 38
31273927 2019
25
Approach to ocular toxoplasmosis including pregnant women. 38
31313714 2019
26
Lyme-associated uveitis: Clinical spectrum and review of literature. 38
31238716 2019
27
Antibiotic treatment for ocular toxoplasmosis: a systematic review and meta-analysis: study protocol. 38
31221217 2019
28
Single Nucleotide Polymorphisms of FCRL3 in Iranian Patients with Behcet's Disease. 38
31341856 2019
29
[Epidemiologic and etiologic patterns of uveitis in a University Hospital]. 38
31164299 2019
30
Patterns of uveitis in children according to age: comparison of visual outcomes and complications in a tertiary center. 38
31248388 2019
31
Dexamethasone Intravitreal Implant Injection in Eyes with Comorbid Hypotony. 38
31371197 2019
32
Under-utilisation of reproducible, child appropriate or patient reported outcome measures in childhood uveitis interventional research. 38
31171027 2019
33
Interferon Alpha 2a and 2b in Ophthalmology: A Review. 38
30950678 2019
34
Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy. 38
31110225 2019
35
Retinal and choroidal abnormalities identified by multispectral imaging in patients with uveitis: Three case reports. 38
31096491 2019
36
Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C. 38
30920588 2019
37
Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients. 38
30959067 2019
38
[Diagnostic Strategy and Therapeutic Dilemma in Acute Posterior and Panuveitis]. 38
30763960 2019
39
Effect of an Injectable Fluocinolone Acetonide Insert on Recurrence Rates in Chronic Noninfectious Uveitis Affecting the Posterior Segment: Twelve-Month Results. 38
30367884 2019
40
Pattern and Outcome of Uveitis in a Tertiary Military Hospital in Thailand. 38
31009267 2019
41
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients. 38
30660771 2019
42
Sero-molecular detection, multi-locus genotyping, and clinical manifestations of ocular toxoplasmosis in patients in northwest Iran. 38
30624725 2019
43
Dual-target, real-time PCR for the diagnosis of intraocular Toxoplasma gondii infections. 38
30636207 2019
44
Human toxocariasis seroprevalence among patients with uveitis in Alborz Province, Iran. 38
30922047 2019
45
Bartonella henselae- and quintana-associated uveitis: a case series and approach of a potentially severe disease with a broad spectrum of ocular manifestations. 38
30852734 2019
46
Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. 38
30821569 2019
47
Characteristics of Behcet's Disease in the American Southwest. 38
30952423 2019
48
Presumed tuberculous uveitis in a university-based tertiary referral center in Saudi Arabia. 38
29318438 2019
49
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. 38
30099655 2019
50
Clinical Profile and Visual Outcomes of Ocular Syphilis: A Five-year Review in Hospital Universiti Sains, Malaysia. 38
31007973 2019

Variations for Posterior Uveitis

Expression for Posterior Uveitis

Search GEO for disease gene expression data for Posterior Uveitis.

Pathways for Posterior Uveitis

Pathways related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 TNF IL6 IL2RA IL2 IFNG
2
Show member pathways
12.76 TNF IL6 IL2RA IL2 IFNG
3 12.72 IL6 IL2RA IL2 IFNG
4
Show member pathways
12.66 TNF IL6 IL2RA IL2
5
Show member pathways
12.53 TNF IL2RA IL2 IFNG
6
Show member pathways
12.48 TNF IL6 IL2 IFNG
7
Show member pathways
12.47 TNF IL6 IL2 IFNG
8 12.46 TNF IL2RA IL2 IFNG
9
Show member pathways
12.45 TNF IL6 IL2RA IL2 IFNG
10
Show member pathways
12.3 IL6 IL2RA IL2 IFNG
11 12.26 TNF IL6 IL2RA IL2
12
Show member pathways
12.25 TNF IL6 IL2 IFNG
13
Show member pathways
12.22 TNF IL6 IFNG
14 12.13 TNF IL6 IFNG
15
Show member pathways
12.11 TNF IL6 IL2
16
Show member pathways
12.1 TNF IL6 IL2RA IL2 IFNG
17 12.08 TNF IL6 IFNG
18
Show member pathways
12.08 TNF IL6 IFNG
19
Show member pathways
11.98 IL2RA IL2 IFNG
20
Show member pathways
11.98 IL6 IL2RA IL2 IFNG
21
Show member pathways
11.95 TNF IL6 IFNG
22
Show member pathways
11.95 TNF IL6 IL2 IFNG
23
Show member pathways
11.89 IL2RA IL2 IFNG
24 11.86 TNF IL6 IL2 IFNG
25 11.84 TNF IL6 IFNG
26 11.82 TNF IL6 IL2RA
27 11.79 TNF IL6 IFNG
28 11.77 IL6 IL2RA IL2 IFNG
29 11.73 IL6 IL2 IFNG
30 11.66 TNF IL2RA IL2 IFNG
31
Show member pathways
11.61 TNF IL2RA IL2 IFNG
32 11.57 TNF IL6 IL2 IFNG
33 11.52 TNF IL6 IL2 IFNG
34 11.47 TNF IL6 IFNG
35 11.46 TNF IL2 IFNG
36 11.43 IL2RA IL2 IFNG
37
Show member pathways
11.42 TNF IL6 IL2 IFNG
38 11.42 TNF IL6 IL2RA IL2 IFNG
39 11.41 TNF IL6 IFNG
40
Show member pathways
11.34 TNF IL2RA IL2 IFNG
41 11.32 TNF IL6 IFNG
42 11.26 TNF IL6
43 11.26 IL2RA IL2 IFNG
44 11.24 TNF IL6 IFNG
45 11.2 TNF IL6
46
Show member pathways
11.17 IL2RA IFNG
47 11.17 IL2RA IL2 IFNG
48 11.16 TNF IL6 IL2 IFNG
49 11.12 IL2 IFNG
50 11.11 TNF IL6 IL2

GO Terms for Posterior Uveitis

Cellular components related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 TNF RBP3 IL6 IL2 IFNG CFH

Biological processes related to Posterior Uveitis according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.8 TNF IL6 IL2RA IL2
2 MAPK cascade GO:0000165 9.79 TNF IL2RA IL2
3 positive regulation of protein phosphorylation GO:0001934 9.77 TNF IL2 IFNG
4 immune response GO:0006955 9.72 TNF IL6 IL2RA IL2 IFNG
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IL6 IL2 IFNG
6 positive regulation of activated T cell proliferation GO:0042104 9.61 IL2RA IL2
7 positive regulation of protein complex assembly GO:0031334 9.61 TNF IFNG
8 negative regulation of neurogenesis GO:0050768 9.6 TNF IL6
9 positive regulation of osteoclast differentiation GO:0045672 9.58 TNF IFNG
10 positive regulation of T cell differentiation GO:0045582 9.58 IL2RA IL2
11 positive regulation of T cell proliferation GO:0042102 9.58 IL6 IL2RA IL2
12 positive regulation of chemokine production GO:0032722 9.57 TNF IL6
13 positive regulation of glial cell proliferation GO:0060252 9.56 TNF IL6
14 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.55 TNF IFNG
15 positive regulation of immunoglobulin secretion GO:0051024 9.54 IL6 IL2
16 humoral immune response GO:0006959 9.54 TNF IL6 IFNG
17 interleukin-2-mediated signaling pathway GO:0038110 9.52 IL2RA IL2
18 negative regulation of lipid storage GO:0010888 9.51 TNF IL6
19 positive regulation of neuroinflammatory response GO:0150078 9.46 TNF IL6
20 negative regulation of lymphocyte proliferation GO:0050672 9.43 IL2RA IL2
21 regulation of T cell homeostatic proliferation GO:0046013 9.26 IL2RA IL2
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.16 TNF IFNG
23 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 TNF IFNG
24 regulation of regulatory T cell differentiation GO:0045589 8.8 IL2RA IL2 IFNG

Molecular functions related to Posterior Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 IL2 IFNG

Sources for Posterior Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....